Background: We compared the long-term cardiac adverse event after SES and PES implantation in patients with diabetes. Method: Five hundred seventy eight patients with diabetes were consecutively enrolled in KOMATE registry (non-insulin dependent diabetes mellitus, n = 555). We assessed the adverse cardiac events [cardiovascular death, non-fatal MI, and ischemic driven target vessel revascularization (TVR)] and stent thrombosis (ST) according to the definition of ARC between SES and PES (SES, n = 424, PES, n = 187). Mean follow-up duration was 34 month (range, 1-53). Result. The baseline characteristics were similar between two groups, except for older age in PES group (p=0.001). During the follow-up, adverse cardiac event occurred in 77 cases [32 cardiovascular deaths, 13 non-fatal MI, 32 ischemic driven TVR and 6, 9 and 25 cases of ST (definite, probable and total including possible)]. There was no significant difference for event rate [SES = 49 (11.6 %) vs. PES = 28 (15.0 %), p = 0.39] and event-free survival (log rank test = 0.25) on MACE between two groups. Also, two type of stents were similar in rate [SES = 9 (2.2 %) vs. PES 6 (3.3 %), p = 0.42] and event free survival (log rank test = 0.44) for the definite and probable stent thrombosis. Conclusion: Our data demonstrated that long-tem cardiac outcome were not significantly different between SES and PES in patients with diabetes. Although the rate of stent thrombosis was not significantly different, higher trend was shown on both DES in diabetes during long-term follow-up.